Phase II study of Tomaralimab (OPN-305): solid organ transplantation

Following the successful completion of the Phase I trial of Tomaralimab in Healthy volunteers, Opsona Therapeutics have now completed a three-part, multi-centre, Phase II study of Tomaralimab (OPN-305) in renal transplant patients at high risk of developing DGF. Further information can be located at https://www.clinicaltrials.gov/ct2/show/NCT01794663?term=opsona&rank=1.

DGF is a complication that occurs in the first few days after the transplantation of a solid organ, when the transplanted organ function is compromised.